Cardiovascular disease and T1D: Advancing breakthroughs in Europe and beyond
What’s happening? Today, Breakthrough T1D co-hosted an event with leading international diabetes organizations to discuss cardiovascular disease (CVD) and type 1 diabetes (T1D)—where we are, challenges that remain, and how we can work together in Europe and beyond to address this need for the T1D community. The focus of the event: Doing more for CVD […]
Q&A with Patti Columbe: A glimpse into her journey with Vertex’s manufactured islets
Breakthrough T1D had the pleasure of speaking with Patti Columbe, a participant in Vertex’s pivotal trial for the manufactured islet therapy zimislecel (formerly VX-880). Patti has been living with type 1 diabetes (T1D) for nearly 39 years. This is one of the most exciting T1D trials in terms of getting us closer to cures for […]
Fundraise Your Way with Breakthrough T1D
With Breakthrough T1D Your Way, you use your time, talent, and creativity to fuel type 1 diabetes research. You name it, we support you!
Ten years of impact: A closer look at Breakthrough T1D’s training awards
To drive our mission forward, Breakthrough T1D financially supports type 1 diabetes (T1D) research through training awards and grants to academic scientists or clinicians, investments in promising companies, conference support, and more. Here, we take a deeper dive specifically into our training awards offered to early-stage researchers to understand the impact and outcomes that these […]
Tzield receives voucher for expedited review in stage 3 T1D
This past week, the FDA and Sanofi, the maker of Tzield, made an important announcement. Tzield, the first disease-modifying therapy approved for delaying onset of stage 3 type 1 diabetes (T1D) in people with stage 2 T1D, has been accepted into the FDA Commissioner’s National Priority Voucher (CNPV) program for people with stage 3 T1D. […]
Civica long-acting insulin available on January 1, 2026
Nearly 3 years ago, Breakthrough T1D joined forces with Civica Rx, a non-profit pharmaceutical company, to manufacture and distribute low-cost insulins. Starting on January 1, 2026, the first of those insulins, insulin glargine-yfgn (a long-acting insulin interchangeable with Lantus®), will be available for purchase. 5 Pens, No More Than $55 – for anyone While we […]
Two truths and a lie: Separate T1D facts from fiction
There are a lot of commonly believed myths about type 1 diabetes (T1D). Play our game to separate fact from fiction.
Celebrating Halloween with type 1 diabetes
Tips for families on juggling type 1 diabetes with the super sweet fun of Halloween.
The Nobel Prize goes to… Immunologists (with a Breakthrough T1D connection!)
The Nobel Prize in Physiology or Medicine went to three immunologists, including one, Fred Ramsdell, who founded a T1D Fund company.
Managing cold and flu with type 1 diabetes
When living with type 1 diabetes (T1D), illnesses like cold and flu require extra attention. Get tips on managing T1D when sick.
